摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-氯-1-甲基-3-(三氟甲基)吡咯-4-羧酸 | 128455-63-0

中文名称
5-氯-1-甲基-3-(三氟甲基)吡咯-4-羧酸
中文别名
5-氯-1-甲基-3-三氟甲基-1H-吡唑-4-羧酸
英文名称
5-chloro-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid
英文别名
5-chloro-1-methyl-3-trifluoromethylpyrazole-4-carboxylic acid;5-Chloro-1-Methyl-3-(Trifluoromethyl)-1H-Pyrazole-4-Carboxylic Acid;5-chloro-1-methyl-3-(trifluoromethyl)pyrazole-4-carboxylic acid
5-氯-1-甲基-3-(三氟甲基)吡咯-4-羧酸化学式
CAS
128455-63-0
化学式
C6H4ClF3N2O2
mdl
——
分子量
228.558
InChiKey
IKGVBNQPAJOSFP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    201 °C
  • 沸点:
    284.4±40.0 °C(Predicted)
  • 密度:
    1.71±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    55.1
  • 氢给体数:
    1
  • 氢受体数:
    6

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 安全说明:
    S26,S36/37/39,S45
  • 危险类别码:
    R34
  • 海关编码:
    2933199090

SDS

SDS:0ef440b9b16f73f94532d959badd56a5
查看
Name: 5-Chloro-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid Material Safety Data Sheet
Synonym:
CAS: 128455-63-0
Section 1 - Chemical Product MSDS Name:5-Chloro-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
128455-63-0 5-Chloro-1-methyl-3-(trifluoromethyl)- unlisted
Hazard Symbols: C
Risk Phrases: 34

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 128455-63-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 202 - 204 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H4ClF3N2O2
Molecular Weight: 228.56

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 128455-63-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Chloro-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 128455-63-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 128455-63-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 128455-63-0 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    新型含苯并咪唑部分的吡唑羧酰胺和烟酰胺衍生物的设计,合成,抗真菌活性和3D-QSAR研究†
    摘要:
    设计并合成了一系列含有苯并咪唑部分的新型吡唑羧酰胺和烟酰胺衍生物,作为抗真菌候选药物。所有目标化合物均通过FTIR,1 H NMR,13 C NMR,HRMS和元素分析技术进行了表征。化合物T1的结构通过单晶X射线衍射分析进一步确认。在体外评估了目标化合物对四种植物病原真菌(灰葡萄孢,立枯根瘤菌,禾谷镰刀菌和黑斑病菌)的抗真菌活性。)通过菌丝体生长抑制方法。生物测定结果表明,一些化合物对显示出良好的抗真菌活性灰霉病以100μgML -1相比其他三个真菌。为了更好地探索结构-活性关系(SAR),测定并评估了目标化合物对灰葡萄孢的EC 50值。随后,基于被测化合物对灰葡萄孢的抑制活性,使用比较分子场分析(CoMFA)技术进行了3D定量结构-活性关系(3D-QSAR)研究。分子建模结果显示具有交叉验证的q 2的良好预测能力和非交叉验证的r 2值分别为0.578和0.850。
    DOI:
    10.1039/c8nj05150j
  • 作为产物:
    描述:
    1-Methyl-3-(trifluoromethyl)-1H-pyrazol-5-ol 在 potassium permanganate三氯氧磷 作用下, 以 丙酮 为溶剂, 反应 12.0h, 生成 5-氯-1-甲基-3-(三氟甲基)吡咯-4-羧酸
    参考文献:
    名称:
    新型含苯并咪唑部分的吡唑羧酰胺和烟酰胺衍生物的设计,合成,抗真菌活性和3D-QSAR研究†
    摘要:
    设计并合成了一系列含有苯并咪唑部分的新型吡唑羧酰胺和烟酰胺衍生物,作为抗真菌候选药物。所有目标化合物均通过FTIR,1 H NMR,13 C NMR,HRMS和元素分析技术进行了表征。化合物T1的结构通过单晶X射线衍射分析进一步确认。在体外评估了目标化合物对四种植物病原真菌(灰葡萄孢,立枯根瘤菌,禾谷镰刀菌和黑斑病菌)的抗真菌活性。)通过菌丝体生长抑制方法。生物测定结果表明,一些化合物对显示出良好的抗真菌活性灰霉病以100μgML -1相比其他三个真菌。为了更好地探索结构-活性关系(SAR),测定并评估了目标化合物对灰葡萄孢的EC 50值。随后,基于被测化合物对灰葡萄孢的抑制活性,使用比较分子场分析(CoMFA)技术进行了3D定量结构-活性关系(3D-QSAR)研究。分子建模结果显示具有交叉验证的q 2的良好预测能力和非交叉验证的r 2值分别为0.578和0.850。
    DOI:
    10.1039/c8nj05150j
点击查看最新优质反应信息

文献信息

  • 縮合二環式ヘテロ環誘導体
    申请人:第一三共株式会社
    公开号:JP2016141632A
    公开(公告)日:2016-08-08
    【課題】優れたレチノイン酸受容体関連オーファン受容体γt阻害作用を有し、乾癬等の治療薬として有用な化合物の提供。【解決手段】一般式(I)で表される化合物又はその薬理上許容される塩。[環Aはピロール環、イミダゾール環又はピラゾール環;環Bは置換/非置換のベンゼン環、シクロヘキサジエン環、シクロペンテン環、シクロヘキセン環等;R1はH、ハロゲン原子等;R2はH、ハロゲン原子、C1−C6アルキル基等;式=Q−T−で表される基は式=CH−CH=CH−で表される基等;Zは式=CH−で表される基等;式−U−V(CO2H)−W−で表される基は、式−CH=CH−C(CO2H)=CH−で表される基等]【選択図】なし
    提供具有优良的视黄醇酸受体相关孤儿受体γt抑制作用,并且作为银屑病等治疗药物有用的化合物。通式(I)表示的化合物或其药理上可接受的盐。【环A为吡咯环、咪唑环或吡唑环;环B为取代/非取代的苯环、环己二烯环、环戊二烯环、环己烯环等;R₁为H、卤原子等;R₂为H、卤原子、C₁−C₆烷基等;基=Q−T−表示的基为基=CH−CH=CH−等;Z为基=CH−等;基表示为式−U−V(CO₂H)−W−的基为,基表示为式−CH=CH−C(CO₂H)=CH−等】【选择图】无
  • SUBSTITUTED HETEROARYL CARBOXYLIC ACID HYDRAZIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS
    申请人:Bayer CropScience Aktiengesellschaft
    公开号:US20180206498A1
    公开(公告)日:2018-07-26
    The invention relates to substituted heteroaryl carboxylic acid hydrazides of general formula (I) or salts thereof, wherein the groups of formula (I) have the definitions stated in the description, for increasing the stress tolerance in plants with respect to abiotic stress, and also for strengthening plant growth and/or for increasing plant yield.
    该发明涉及通式(I)的取代杂环芳基羧酸腙或其盐,其中通式(I)中的基团具有描述中所述的定义,用于增加植物对非生物胁迫的耐受性,同时也用于增强植物生长和/或增加植物产量。
  • [EN] COMPOUNDS FOR THE TREATMENT OF HEPATITIS C<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DE L'HÉPATITE C
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2010093359A1
    公开(公告)日:2010-08-19
    The invention encompasses selected compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    这项发明涵盖了公式I的选定化合物,以及使用这些化合物的组合物和方法。这些化合物对丙型肝炎病毒(HCV)具有活性,并可用于治疗感染HCV的人。
  • Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase
    申请人:Anderson Kevin William
    公开号:US20070225280A1
    公开(公告)日:2007-09-27
    Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.
    本文提供了以下式(I)的化合物: 以及其药学上可接受的盐,其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如II型糖尿病和代谢综合征等疾病是有用的。
  • 新型EP4拮抗剂的合成及其在癌症和炎症中的用途
    申请人:湖北生物医药产业技术研究院有限公司
    公开号:CN113354585A
    公开(公告)日:2021-09-07
    本发明提出了一种有效拮抗EP4的新化合物,其为式I所示化合物,或者式I所示化合物的互变异构体、立体异构体、水合物、溶剂化物、药学可接受的盐或前药:其中:R1选自‑CH3、‑CHF2和‑CF3;R2选自C2‑C6烷基、C3‑C6环烷基、被卤素取代的C2‑C6烷基、被卤素取代的C3‑C6环烷基;R3选自氢、卤素、C1‑C2烷基、被氟取代的C1‑C2烷基;R4选自氢、卤素、C1‑C6烷基、C1‑C6烷氧基、被卤素取代的C1‑C6烷基、被卤素取代的C1‑C6烷氧基。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺